PCYC-1128-CA - A phase1b/2 study of Ibrutinib Combination Therapy in selected
advanced gastrointestinal and genitourinary tumors (bladder, colon, gastric, renal)
What type of cancer? What stage?
Advanced GU cancer (bladder and renal).
Who is eligible?
Patients who have received prior chemotherapy.
How will I be treated?
Patients will receive Ibrutinib with other chemotherapy or biologic therapy.
S1605
S1605 - Phase II trial of Atezolizumab in BCG-unresponsive non-muscle invasive
bladder cancer.
What type of cancer? What stage?
Early bladder cancer.
Who is eligible?
Men with bladder cancer who have received BCG.
How will I be treated?
Atezolizumab, an immunotherapy that acts on PDL1.
A031701
A031701 - A Phase II study of dose-dense Gemcitabine plus Cisplatin (ddGC)
in patients with muscle-invasive bladder cancer with bladder preservation
for those patients whose tumors harbor deleterious DNA Damage Response
(DDR) gene alterations.
What type of cancer? What stage?
Bladder cancer.
Who is eligible?
Patients must have muscle-invasive bladder cancer. They will be tested
for a DDR mutation.
How will I be treated?
This study looks at treating with chemotherapy for bladder preservation.
A031501
A031501 - Phase III randomized adjuvant study of MK-3475 (Pembrolizumab)
in muscle invasive and locally advanced urothelial carcinoma (AMBASSADOR)
versus observation.
What type of cancer? What stage?
Urothelial cancers (bladder, ureter, or kidney).
Who is eligible?
Patients who have had complete resection (TURBT that completely removed
tumor is okay).
How will I be treated?
The study looks at treating with Pembrolizumab, an anti-PD-1 immunotherapy.
SI602
SI602 - A Phase III randomized trial to evaluate the influence of BCG strain
differences and T Cell priming with intradermal BCG intravesical therapy
for BCG-naïve high-grade non-muscle invasive bladder cancer.
What type of cancer? What stage?
Bladder cancer (no prior treatment).
Who is eligible?
High-grade muscle-invasive bladder cancer.
How will I be treated?
This study evaluates the effect of adding a vaccine to BCG therapy.
For physicians: more information about this specific trial at
clinicaltrials.gov.
